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ABSTRACT
Estrogen (E2) has been suggested to have a protective role in attenuating 
hepatocellular carcinoma (HCC) development. miRNAs have great potential as 
biomarkers and therapeutic agents owing to their ability to control gene expression. 
However, little is known about the mechanism underlying the protective role of 
E2 in hepatocarcinogenesis and the effects of E2 on apoptotic miRNAs expression. 
Using miRNA PCR array, we found more than 2-fold alteration was observed in 25 
upregulated and 10 downregulated apoptotic miRNAs in E2-treated cells. Among 
these miRNAs, we found expression of miR-23a was related to p53 functional status 
in the male-derived liver cell-lines. We demonstrated that E2 via ERα transcriptionally 
activated miR-23a and p53 expression, and thus enhanced p53 activation of miR-23a 
expression. Moreover, miR-23a expression correlated inversely with the expression 
of target gene X-linked inhibitor of apoptosis protein (XIAP), but positively with the 
caspase-3/7 activity. Decreasing of XIAP might contribute to caspase-3 activity and 
cell apoptosis. Taken together, our findings reveal a novel E2-signaling mechanism 
in regulating miRNAs expression for controlling apoptosis in liver cells. Delineating 
the role of E2 in regulating the activation of p53 and miR-23a, expression in HCC is 
crucial to the understanding of the sex difference observed in HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
common malignant cancer and the third leading cause of 
cancer-related death in the world. The development of 
HCC is considered to be the most serious result of chronic 
liver diseases, including viral hepatitis B and C, cirrhosis 
due to other causes and alcoholic liver diseases [1]. 
Although the incidence of HCC worldwide is increasing 
[2], our understanding of the underlying molecular 
pathogenesis pathways in HCC is still limited.
Epidemiological data indicate that regardless of 
etiology, the incidence of HCC is higher in males than 
in females, with a male to female ratio ranging between 
3–5 to 1 [3]. This sex difference is also found in the 
development of cirrhosis. This favourable outcome in 
female patients is attenuated after menopause [4]. Both 
epidemiologic evidence and results from animal studies 
have shown that estrogen (E2) may have a tumor 
protective role in female [4–6]. However, the mechanisms 
governing these phenomena are largely unknown.
MicroRNAs (miRNAs) are a family of small 
noncoding RNA molecules that regulate target genes 
expression at the post-transcriptional level. They are 
involved in stem cell self-renewal, cellular development, 
proliferation, and apoptosis [7]. Growing evidence 
indicates that miRNA is differentially expressed during 
development of many types of cancer, including liver 
cancer [8–10]. These findings suggest that miRNAs may 
play an important role in carcinogenesis as a novel class 
of oncogenes or tumor-suppressor genes. Thus, miRNAs 
have been considered as potential targets for cancer 
therapy as well as diagnostic tools.
The homeostatic balance between cell proliferation 
and cell death rate is critical for maintaining normal 
physiological processes. Aberrant regulation of apoptotic 
cell death mechanisms is one of the hallmarks of cancer 
development and progression, and many cancer cells 
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exhibit significant resistance to apoptosis signaling [11]. 
Increasing number of miRNAs have been implicated in 
regulating cell death [12]. They either function as pro-
apoptotic or anti-apoptotic miRNAs which regulate 
target anti-apoptotic or pro-apoptotic mRNAs expression 
respectively, and thus regulate cell apoptosis [13, 14]. 
Deregulation of these apoptotic-miRNAs might contribute 
to the development of disease, including cancers. Recent 
investigations have reported that miRNAs are involved 
in E2 signaling pathway [15, 16]. We therefore speculate 
that some of these miRNAs may contribute to the unique 
gender disparity observed in HCC. Particularly, it will be 
interesting to determine if E2 plays a role in regulating 
specific apoptotic miRNA(s) expression, thus inhibiting 
HCC development.
The aims of this study were to 1) evaluate the 
effects of E2 on apoptotic miRNAs expression; 2) 
explore the possible molecular mechanisms underlying 
the differential expression of miR-23a observed in HCC 
cells; and 3) identify whether E2-regulated miRNA-23a 
subsequently control target genes expression and cell 
apoptosis in HCC.
RESULTS
Identification of estrogen-regulated apoptotic 
miRNAs
We profiled the miRNA expression in response 
to E2 treatment in SNU-387 cells. Among the 84 
apoptotic miRNAs analyzed (Figure 1A), 25 miRNAs 
were upregulated (>2.0 fold), whereas 10 miRNAs were 
downregulated (>2.0 fold) compared with the untreated 
control cells (Figure 1B and Supplementary Table S2). 
Figure 1: Deregulation of apoptotic miRNA expression in SNU-387 liver cancer cells following 10–8M estrogen (E2) 
treatment for 24 hours. A. Heat map generated from PCR array data reflecting miRNAs expression values in E2-treated cells versus 
untreated controls. This graph represents log2 fold-regulation data from two sample groups on a 96-well plate layout. Red indicates up-
regulation; green indicates down-regulation; black indicates no change; and grey indicates not determined (the recommended lower limit 
of detection when both samples with Ct ≥ 35). The bar code on the bottom represents the color scale of the log2 values. B. List of the 
miRNAs that were upregulated (>2.0 fold) and downregulated (>2.0 fold) in E2-treated cells as determined by miRNA PCR array analysis. 
C. Confirmation of six aberrantly expressed miRNAs using quantitative real-time PCR. Cells were starved overnight in serum-free medium 
before treatment with 10−8M E2 for 24 hours. The expression of miRNAs was normalized with internal control U6 SnRNA and compared 
with vehicle-treated control cells calculated using ΔΔCt method. Data are expressed as means ± SEM from three individual experiments. 
**p < 0.05 and *p < 0.01.
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Based on their levels of distinct differential expression, as 
well as their relevance to cancer development as revealed 
by literature review [13, 17–21], we selected 6 miRNAs 
for further validation. Microarray results were confirmed 
by evaluating the expression of miRNAs using real-time 
PCR. We found miR-23a, miR-26b, miR-92 and miR-122 
were significantly upregulated (all with p < 0.05), whereas 
miR-143 and miR-17 were significantly downregulated 
when compared with untreated control cells (p < 0.01 for 
miR-143; p < 0.05 for miR-17) (Figure 1C). This indicated 
that the real-time PCR validation results were consistent 
with the microarray measurements.
In silico analysis of miRNA target genes
We speculated that these E2-regulated miRNAs 
might play a role in the regulation of apoptosis in HCC. 
Therefore, we performed an in silico search for target 
genes of these miRNAs, with special focus on apoptosis-
related genes. E2 acts through estrogen receptors (ERs). 
miR-23a processes four ERα-biding sites in its regulatory 
region [22], and is implicated in the regulation of seve-
ral important apoptosis-related genes (Supplementary 
Table S3). Thus, miR-23a was chosen to be a candidate 
to investigate apoptotic miRNA involvement in E2 
signaling and selected for further analysis.
Endogenous expression of miR-23a in liver 
cancer cell-lines
We measured the expression of miR-23a in 6 liver 
cell-lines. As shown in Figure 2A, miR-23a expression in 
the female-derived cell line SNU-387 was significantly 
higher than that in three of the male-derived cell-lines 
Hep3B, Huh7 and HepG2.2.15 (p < 0.001). However, 
miR-23a expression in the other 2 male liver cell-lines, 
L02 and HepG2, was comparable to SNU-387. Notably, 
among the 5 male liver cell-lines, the expression levels 
of miR-23a were related to the mutational status of the 
tumor suppressor gene p53 in the cells (Figure 2A). When 
Figure 2: Expression of the tumor suppressor p53 and miR-23a in liver cancer cells. A. Differential expression of miR-23a 
in relation to the p53 functional status in liver cancer cell-lines. B. Effect of doxorubicin (DOX) on the expression of miR-23a in p53+/+ 
HepG2 and p53−/− Hep3B cells. C. Transient knockdown of p53 by p53-siRNA suppressed p53 mRNA and protein expression. D. Effect of 
p53 knockdown and DOX treatment on miR-23a expression in HepG2 cells (***p < 0.0001, **p < 0.001 and *p < 0.01).
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compared with cell-lines with wild-type p53 (L02 and 
HepG2), cell-lines with null/mutated p53 (Hep3B [p53-
null], Huh7 [p53-mutated] and HepG2.2.15 [p53-LOH]) 
had significantly lower expressions of miR-23a (all p < 
0.001). Although the female cell-line SNU-387 has a p53-
heterozygotic genotype [23, 24], its endogenous miR-
23a expression level was comparable to that in L02 and 
HepG2 cells with wild-type p53 (Figure 2A).
P53-induced the expression of miR-23a
To confirm whether the difference in miR-23a 
expression was related to p53 functional status, we altered 
the p53 activity in HepG2 (p53+/+) and Hep3B (p53−/−) 
and measured their subsequent effects on miR-23a 
expression. As shown in Figure 2B, following treatment 
of cells with doxorubicin (DOX), a potent p53 inducer, 
miR-23a expression levels was significantly increased 
in HepG2 cells when compared with non-treated control 
cells (p < 0.0001 at 12 hr; p < 0.01 at 24 hr). In contrast, 
DOX treatment did not induce the expression of miR-23a 
in Hep3B cells at all the time points (Figure 2B). This 
observation was further confirmed by siRNA-mediated 
p53 knockdown in HepG2 cells (Figure 2C). As shown in 
Figure 2D, in HepG2 cells transfected with control siRNA, 
DOX treatment significantly increased the expression of 
miR-23a (p < 0.001) when compared with cells without 
DOX treatment. However, in HepG2 cells with siRNA-
mediated p53 knockdown, the expression of miR-23a was 
significantly lower when compared with cells transfected 
with control siRNA, regardless of the presence or absence 
of DOX, (both p < 0.001) (Figure 2D).
The above results indicated that, in the male-derived 
HepG2 cells, both expression and activation of p53 
were crucial to augment miR-23a expression. However, 
in the female-derived SNU-387 cells, despite its p53-
heterozygotic genotype, its miR-23a expression levels 
were comparable with other cell-lines with functional 
p53 (Figure 2A). As miR-23a expression in SNU-
387 was upregulated after E2 treatment (Figure 1 and 
Supplementary Table S2), we studied whether E2 affected 
p53 expression. As shown in Figure 3C, the expression of 
p53 in SNU-387 was significantly increased when treated 
with 10−8M E2 (p < 0.001; compared with untreated 
controls), indicating that E2 may involve in p53-mediated 
regulation of miR-23a expression.
Estrogen increases p53 and miR-23a expression 
via estrogen receptor-α
Next, we studied whether the effects of E2 on 
miR-23a and p53 expression was mediated via the ERα 
receptor. As shown in Figure 3A, SNU-387 cells had a 
higher expression of ERα than other male-derived cell-
lines. When SNU-387 cells were treated with E2, an 
increased in ERα mRNA expression was observed, with 
a maximum increase of nearly 3-fold at 10−8M E2 (p < 
0.01) (Figure 3B). In Hep3B cells, in which no expression 
of ERα was detected (Figure 3A), treatment of E2 did 
not induce the expression of both ERα and p53 (data not 
shown). This might account for the low expression of 
miR-23a in Hep3B cells (Figure 2A).
To further confirm that E2 regulates the expression 
of p53 through ERα, we pretreated SNU-387 with the 
ERα antagonist ICI 182,780 and found that it completely 
blocked the induction of ERα and p53 expression by E2 
(Figure 3B and 3C). In addition, transient knockdown 
of ERα was achieved by siRNA-ERα in SNU-387 cells 
with or without E2 treatment that led to a decrease in p53 
mRNA (p < 0.01 and p < 0.001 respectively) and protein 
expression levels (Figure 3D). Consistent with the above 
observations, knockdown of ERα decreased the expression 
of miR-23a in SNU-387 cells with or without E2 treatment 
(both p < 0.0001) (Figure 3E). These results indicated that 
upon ligand E2 binding, ERα activates both p53 and miR-
23a expression at the transcriptional level.
The effects of miR-23a on expression of  
anti-apoptotic protein XIAP
We also studied the expression of other target 
genes of miR-23a. Among the potential targets of miR-
23a (Supplementary Table S3), the X-linked inhibitor 
of apoptosis protein (XIAP) was chosen for further 
analysis. XIAP is the most potent anti-apoptotic protein 
and has been demonstrated to be overexpressed in HCC 
and counteract apoptosis [25–27]. Furthermore, in silico 
analysis predicted that there were five potential miR-
23a-binding sites in the 3′-UTR of XIAP (Supplementary 
Figure S1). The interaction between miR-23a and XIAP 
in SNU-387 cells was confirmed by gain-of-function and 
loss-of-function approaches. Transfection of cells with 
anti-miR-23a, which decreased the level of endogenous 
miR-23a (Figure 4A), led to a significant increase in 
the expression of the target XIAP at both mRNA and 
protein levels (p < 0.001) (Figure 4B and 4C). Similarly, 
transfection of cells with miR-23a mimic, which 
significantly increased the level of miR-23a (p < 0.001) 
(Figure 4A), resulted in the suppression of target XIAP 
at both mRNA and protein levels (p < 0.0001) (Figure 
4B and 4C). When cells were treated with E2, miR-23a 
expression was augmented and XIAP expression was 
decreased (both p < 0.001) (Figure 4B and 4C). These 
findings suggest that XIAP expression is down-regulated 
by miR-23a.
E2, miR-23a, and cell apoptosis
XIAP inhibits cell death by binding to apoptotic 
executioners, caspase-3/7. Therefore, we assessed whether 
miR-23a regulates the activity of caspase-3/7 in SNU-387 
cells. As shown in Figure 5A, the activity of caspase-3/7 
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was elevated by 18% in E2 treated cells when compared 
with control cells (p < 0.05). This induction of caspase-3/7 
activity was abolished by transient knockdown of ERα. 
To further prove E2 increases caspase-3/7 activity via 
miR-23a, we transfected miR-23a mimic or anti-miR-23a 
into SNU-387 and found that miR-23a mimic increased 
caspase-3/7 activity by 35% and anti-miR-23a suppressed 
caspase-3/7 activity by 26% (both p < 0.005; Figure 5A).
In addition to caspase-3/7 activity, we measured the 
expression of capsase-3/7. Caspase-7 is also a predicted 
target of miR-23a (Supplementary Table S3). Neither 
E2 nor miR-23a had any effect on caspase-7 mRNA 
and protein expression (Figure 5B). This suggested that 
caspase-7 expression was not regulated by miR-23a in 
liver cells, and the induction in caspase-3/7 activity was 
likely due to activation of caspase-3. This was confirmed 
by the increase in caspase-3 expression in cells treated 
with E2 (p < 0.0001) and miR-23a mimic (p < 0.01) 
and the decreased caspase-3 expression in anti-miR-23a 
transfected cells (p < 0.001; Figure 5C). In concordance 
with the above findings, E2 and miR-23a mimic increased 
pro-caspase-3 (32kD) and active caspase-3 (17kD) protein 
expressions, whereas anti-miR-23a suppressed both forms 
of caspase-3 protein expressions (Figure 5D). These 
results indicate that miR-23a decreased XIAP expression, 
which subsequently induced caspase-3 expression and 
activity.
Finally, to extend the above findings on activation 
of caspase 3 and cell death, we assessed the apoptotic 
population in E2-treated SNU-387 cells by Hoechst/PI 
double staining and flow cytometry analysis. As shown 
in Figure 6A, the number of cells underwent apoptotic 
cell death was higher in E2 treated group than controls, 
as characterized by condensation of chromatin with 
Hoechst/PI double staining. This was consistent with the 
data obtained from flow cytometry analysis. E2 treatment 
increased the percentage of early (Annexin-V FITC 
positive) and late (Annexin-V FITC and PI positive) 
apoptotic cells with relative to control cells without 
treatment (Figure 6B). Results of both analyses showed 
significant increase in the number of apoptotic cells in 
SNU-387 with E2 treatment compared with control cells 
(p < 0.0001) (Figure 6C). The apoptotic cell death with 
E2 treatment, which increased with time confirming the 
Figure 3: Estrogen induces p53 and miR-23a expression in SNU-387 cells. A. Endogenous mRNA and protein expression 
of estrogen receptor ERα was assessed in liver cell-lines. B. and C. ERα and p53 mRNA expression in SNU-387 cells with E2 treatment 
(10−10-10−7M) or with pretreatment of 1 μM ICI-182,780 (ICI) for 24 hours were analyzed by quantitative RT-PCR. D. Relative mRNA and 
protein expression of p53 and protein expression of ERα with or without knockdown of ERα by ERα siRNA was measured in SNU-387 
cells. E. Quantitative RT-PCR analysis of the effects of E2 on miR-23a expression in SNU-387 cells with or without ERα knockdown. Data 
are expressed as means ± SEM from three individual experiments (***p < 0.0001, **p < 0.001 and *p < 0.01).
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apoptotic effect of E2 in SNU-387 cells were showed in 
Supplementary Figure S3. Taken together, these findings 
suggest a novel relationship between E2 treatment, 
miR-23a activation and the commitment of the cells to 
apoptotic pathway.
DISCUSSION
Deregulation of several miRNAs have been reported 
to be involved in controlling apoptosis and carcinogenesis 
[12]. E2 has been implicated in gender disparity and 
attenuated HCC development [4, 28]. However, attempts 
to determine miRNAs as posttranscriptional regulators in 
E2 signaling in liver cells are scarce. E2 regulates gene 
expression by binding to its receptors (ERs) [29]. The 
activated ERs then translocate into the nucleus, bind to 
DNA, and regulate target gene transcription. As miRNAs 
are themselves genes, they too can also be regulated in 
this manner. Indeed, recent studies have demonstrated that 
ERs bind to regulatory regions upstream of miRNAs and 
stimulate their transcription [30].
Consistent with previous reports in other types 
of cancer [15, 16, 31, 32], we found that E2 treatment 
regulated apoptotic miRNAs expression in HCC. 
Our miRNA PCR array analysis revealed a >2−fold 
upregulation in 25 miRNAs and a >2−fold downregulation 
in 10 miRNAs. A 2-fold difference in one single miRNA 
has been considered to be significant in decreasing the 
expression of multiple target genes and proteins resulting 
in remarkable physiological effects [33, 34]. Notably, we 
found E2 treatment upregulated the tumor suppressive 
miRNAs, miR-26a, miR-92 and miR-122, and suppressed 
the oncomirs miR-143 and miR-17. Expression of these 
tumor suppressive miRNAs and oncomirs have been 
reported to be down-regulated and elevated in HCC, 
respectively [20, 35–39]. The role of miR-23a has been 
reported with varying conclusions. Some early studies 
showed that miR-23a promotes cell proliferation and 
anti-apoptosis [40, 41]. More recent studies demonstrated 
that miR-23a could induce caspase-dependent and 
-independent apoptosis in human embryonic kidney cells 
[42], and granulosa cells [43]. The different effects of 
Figure 4: Gain of function and loss of function analysis on the expression of miR-23a and its effect on X-linked 
inhibitor of apoptosis protein (XIAP) expression in SNU-387 cells. Quantitative analysis on A. miR-23a expression; B. XIAP 
mRNA expression; and C. XIAP protein expression in SNU-387 cells transfected with miR-23a mimic (20 nM) or anti-miR-23a (20 nM), 
or with E2 (10−8M) treatment. Cells were collected for analysis at day 2 after treatment or transfection. Data represent means ± SEM from 
three independent experiments (***p < 0.0001, **p < 0.001 and *p < 0.01).
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miR-23a may be related to the fact that the physiological 
effects of miRNAs are cell-type dependent and disease 
specific [44]. In this study, we found E2 treatment 
induced the expression of miR-23a. This is consistent 
with previous reports indicating that miR-23a is an E2-
responsive miRNA [15, 45].
To our knowledge, the present study is the first to 
show that miR-23a expression was related to functional 
status of p53 in HCC cell-lines. We found that expression 
of miR-23a in male liver cell-lines was dependent on a 
functional p53. Unexpectedly, in the female cell-line 
SNU-387, expression of miR-23a was not completely 
p53-dependent. Thus, other transcriptional mechanisms 
in addition to p53 signaling might contribute to miR-
23a expression. We therefore speculated that there was 
a link between E2 and p53 on the activation of miR-
23a expression. We found that E2 treatment induced the 
expression of both p53 and ERα in an E2-dependent 
manner (Figure 3B and 3C), and transiently knockdown 
of ERα abolished the induction of both p53 and miR-
23a expression (Figure 3D and 3E). This observation 
suggested that upon E2 treatment, ERα might induce 
miR-23a expression either directly by binding to miR-
23a regulatory regions or synergistically by binding to 
regulatory region of p53 to activate its expression, and 
thus increase the expression of miR-23a. In SUN-387 
cells, even one allele of p53 is deficient, the effect of E2 
seemed to overcome the deficit in p53 activity in induction 
of miR-23a expression. Our findings indicate that E2 
treatment has a strong influence on miR-23a expression, 
which in turn affects apoptosis.
Apoptosis serves as a natural constraint to cancer 
formation and development. Overexpression of XIAP 
that counteracts apoptosis has been demonstrated in 
HCC [25, 27]. In this study, we observed a clear inverse 
relationship between the changes of miR-23a levels and 
the expression of its corresponding target gene, XIAP. This 
E2-induced reduction of XIAP expression was mediated by 
Figure 5: Effects of miR-23a on caspase-3/7 activity and apoptosis in SNU-387 cells. A. Caspase 3/7 activity were analyzed in 
SNU-387 cells transfected with miR-23a mimic or anti-miR-23a, or with E2 treatment +/– ERα knockdown (**p < 0.005 and *p < 0.05) for 
24 hours. Similarly, effect of miR-23a mimic, anti-miR-23a, and E2 treatment on B. caspase-7 mRNA and protein expression; C. caspase-3 
mRNA expression; and D. pro-caspase-3 (32KD) and active caspase-3 (17KD) protein levels were analyzed 24 hours after transfection or 
treatment in SNU-387 cells. Data are mean values ± SEM from three independent experiments (***p < 0.0001, **p < 0.001 and *p < 0.01).
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ERα and was associated with an increased caspase-3 mRNA 
and protein expression and enhanced caspase 3/7 activity. 
These findings suggest that E2-activated ERα exerts a post-
transcriptional control on its target gene XIAP, via miR-
23a, and decrease in XIAP expression may contribute to the 
activation of caspase-3 and induction of cell death.
Genome-wide decreases in the miRNAs expression 
are common in malignancy and this in turn contributes to 
aberrant mRNA expression patterns observed in primary 
tumors [10]. p53 has been shown to regulate expression 
of miRNAs involved in tumor suppression and cellular 
senescence [46, 47]. Loss of p53 function can sensitize 
cells to DNA damage due to impaired DNA repair. As a 
result, damaged cells are less likely to undergo apoptosis 
which may lead to malignant transformation [48]. In this 
study, we found E2 treatment increased p53 expression 
and subsequently activated miR-23a, thereby suppressing 
XIAP expression and causing cell-death. Therefore, it is 
reasonable to postulate that E2 exerts a tumor suppressor 
role in HCC by activation of p53 expression and apoptosis. 
This may also explain the sex disparity observed in HCC 
development. In fact, miR-23a mediated XIAP expression 
has been suggested to have a protective effect and 
contributes to the sex difference in brain injury in mice 
[49]. Furthermore, suppression of miR-23a inhibited 
the activation of p53 target genes and cell death in HCC 
cells [50]. Taking these findings together, we propose a 
possible model for the effect of E2 on cellular apoptosis. 
Upon E2 treatment, ERα expression is activated, which 
in turns increases the expression of miR-23a either 
directly or through the synergistic effect of increased p53 
expression. The increased miR-23a expression results in a 
decreased XIAP expression, which subsequently enhances 
caspase-3/7 activity through an increase in caspase 3 
expression. As a result of the induction of both p53 and 
caspase-3/7, cellular apoptosis is enhanced.
Figure 6: Estrogen induced apoptosis in SNU-387 cells. The cells were collected for analysis after treatment with 10−8M E2 for 
24 hours. A. Representative fluorescence images obtained after Hoechst 33258 and propidium iodide (PI) double staining. The nuclei 
of apoptotic cells have highly condensed chromatin that is stained by Hoechst 33258 and PI, indicating by bright blue and red spherical 
nucleus respectively. At least 200 cells in 6 randomly selected areas were counted in treatment and control cells B. Flow cytometry analysis 
of apoptosis by double staining with Annexin-V FITC/PI. Numbers indicate the percentage of cells in each quadrant C. The percentage 
of apoptotic cells (A and B) compared with control cells treated with vehicle (DMSO), respectively was counted from three independent 
experiments. All data were expressed as means ± SEM (**p < 0.001 and ***p < 0.0001).
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In conclusion, this study identified a novel 
relationship between E2, p53 and miR-23a in liver 
cancer cells. Their interactions suggested a possible 
mechanism by which E2 induced cellular apoptosis and 
hence conferred a protective role against HCC. Further 
delineation of the E2-signaling mechanism in regulating 
the activation of p53 and miR-23a expression in HCC 
will be crucial to the understanding of the sex difference 
observed in this disease entity, and may provide a new 
avenue for the development of more efficient therapeutic 
strategies and treatment.
MATERIALS AND METHODS
Cell lines and treatment
The five human liver cancer cell lines (SNU-387, 
Huh7, HepG2, HepG2.2.15 and Hep3B) were obtained 
from the ATCC. The L02 cell line derived from human 
normal liver was obtained from the Shanghai Institutes 
for Biological Sciences, and Chinese Academy of 
Sciences. Only SNU-387, HepG2.2.15 and Hep3B are 
HBV positive cell lines. Cells were cultured in RPMI-
1640 medium without phenol red, supplemented with 
10% charcoal-stripped fetal bovine serum (Invitrogen, 
Carlsbad, CA) in a humidified incubator with 5% CO2 at 
37°C. SNU-387 was a female-derived liver cancer cell-
line, and the others were male-derived cell-lines. Before 
treatment, cells were starved overnight in serum-free 
medium. Unless otherwise stated, cells were generally 
treated with 17β-estradiol (E2) (10−8M) or doxorubicin 
hydrochloride (DOX) (0.5 μM) (Tocris Bioscience, 
Ellisville, MO) for 24 hours.
Transient miRNA and siRNA transfection
Transfection was performed with Lipofectamine 
2000 reagent (Invitrogen) following the manufacturer’s 
protocol. Briefly, 3 × 105 cells were seeded in plates one 
day before transfection to ensure suitable cell confluency 
on the day of transfection. Oligonucleotides (miR-23a 
mimic and anti-miR-23a) (Ambion, Austin, TX) were 
used at a final concentration of 20nM in antibiotic-free 
Opti-MEM medium (Invitrogen). siRNAs (against ERα 
and p53) (Qiagen) were used at a final concentration of 
50nM. siRNAs with non-specific sequences were used as 
controls. Cells were harvested at day 2 post-transfection.
RNA isolation
Total RNA was extracted from cells using TRIzol 
reagent (Invitrogen), according to the manufacturer’s 
instructions. DNA and RNA concentrations and 
integrity were determined using the NanoDrop 2000 
Spectrophotometer (Thermo Fisher Scientific, MA).
miRNA PCR array analyses
Two micrograms of total RNA isolated from E2-
treated (10−8M for 24 hours) or vehicle-treated SNU-387 
cells were reverse-transcribed using the miScript II RT kit 
(Qiagen), following the manufacturer’s protocol. cDNA 
was assayed via an optimized, real-time PCR reaction for 
the expression of 84 apoptosis-related miRNAs using the 
human apoptosis miScript miRNA PCR array (Qiagen). 
Data analysis was performed with the online data analysis 
tool available at http://pcrdataanalysis.sabiosciences.com/
mirna, using the ΔΔCT method of relative quantification. 
Target genes were predicted using in silico analysis by 
PicTar and TargetScan algorithms [51, 52].
Real-time PCR for miRNA and target genes 
expression
For miRNA analysis, mature miRNA was extracted 
from cell lines with or without drug stimulation or 
transfection (as described above). miRNAs were reverse-
transcribed using the TaqMan MicroRNA reverse 
transcription kit (Applied Biosystems, Foster City, CA). 
Real-time PCR was performed using Taqman miRNA 
assays (assay ID: 000399, 000466, 000393, 000407, 
000430, 002245) (Applied Biosystems), according 
to the manufacturer’s instructions. U6 snRNA was 
not responsive to E2 treatment and stable among all 
cell-lines thus was used as the endogenous control 
(Supplementary Figure S2). For target gene analysis, 
total RNA was reverse-transcribed into cDNA using the 
Superscript III First-strand synthesis kit (Invitrogen). 
qPCR and semi-quantitative PCR were performed 
using the SYBR Green PCR master mix (Applied 
Biosystems) and ThermoScript™ RT-PCR System 
(Invitrogen), respectively. GAPDH was used as the 
internal control. Mean Ct was determined from triplicate 
PCRs. The relative expression level was then calculated 
using the ΔΔCT method. Primer sequences are listed in 
Supplementary Table S1.
Caspase activity assay
Caspase 3/7 activity was analyzed using the 
Caspase-GLO 3/7 kit (Promega, Madison, WI) as 
recommended by manufacturer’s instructions. Following 
E2 treatment, SNU-387 and Hep3B cells were transfected 
with miR-23a mimic or anti-miR-23a in a 96-well plate. 
After 24 hours, cells were incubated with medium 
supplemented with 100 μl caspase-3/7 reagent for 3 hours 
at room temperature. Then, luminescence from cleaved 
Oncotarget34950www.impactjournals.com/oncotarget
caspase substrate was measured using the luminometer 
(CLARIOstar, BMG Labtech, Germany). Resulting 
data were expressed as OD values and normalized to 
untransfected control cells. Experiments were performed 
in triplicates.
Apoptosis detection by flow cytometry and 
Hoechst 33258/propidium iodide double staining
SNU-387 cells were treated with E2 (10−8M) for 
24 hours. Cells were harvested (including attached and 
detached cells), washed and resuspended with PBS. For 
flow cytometry analysis, apoptotic cells were determined 
with an Annexin V- FITC Apoptosis Detection Kit (BD 
Pharmingen, SD, USA) according to the manufacturer’s 
protocol. Apoptosis cells were analyzed by using FC500 
flow cytometer (Beckman Coulter, Germany). The data 
were analyzed using Flowjo software (Tree Star, OR, 
USA). For Hoechst 33258 (Sigma) and propidium iodide 
(PI) (Sigma) double staining analysis, cells were incubated 
with Hoechst 33258 (10 μg/mL) and PI (10 μg/mL) for 15 
minutes, and then fixed in 4% formaldehyde for 20 minutes. 
Imaging was detected under a fluorescence microscope 
(Olympus, Tokyo, Japan) at 340 and 620 nm, respectively.
Western blot analysis
Cells were lysed in RIPA buffer with 1 mM 
phenylmethylsulfonyl fluoride (Roche). Protein 
concentration was determined by BCA Protein Assay Kit 
(Thermo Fisher Scientific, MA USA). 20–50 μg of protein 
was loaded on 10% SDS-polyacrylamide gels, transferred 
to a PVDF membrane, blocked with 5% milk, and then 
probed with relevant primary antibodies to XIAP, ER-
α, p53 (Santa Cruz, CA), caspase-3/7 and β-actin (Cell 
Signaling, MA) overnight at 4°C. Protein expression was 
assessed by ECL detection system (GE Healthcare, NJ) 
and band intensities were quantified using the Image J 
software (NIH, Bethesda, MD).
Statistical analysis
Continuous variables were expressed as mean ± 
standard error (SEM) and analyzed using the student’s 
t-test. All statistical analysis was done using GraphPad 
Prism 5.0 (GraphPad Software, Inc. San Diego, CA). 
A p value of less than 0.05 was considered statistically 
significant.
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